帕尼培南/倍他米隆的体外抗菌活性研究

为评价帕尼培南的体外抗菌作用，采用琼脂二倍稀释法测定帕尼培南／倍他米隆对247例临床分离菌的最低抑菌浓度（MIC），并与其它5种抗菌药物进行比较，结果表明，帕尼培与亚胺培南体外抗菌作用相仿，但帕尼培南对流感嗜血杆菌，金黄色葡萄球菌包括耐甲氧西林金葡萄球菌（MRSA）和大肠埃希氏菌体外胺培南对肺炎克雷伯氏菌、大肠埃希氏菌等革兰氏阴性菌作用略逊于美罗培南，帕尼培南体外抗菌 于头孢他啶，头孢哌酮／舒巴坦，苯唑西林等其它受试药物。帕尼培南的体外抗菌活性受接种菌量，培养基PH值和血清浓度影响。结果表明，帕尼培南是治疗多重耐药菌所致院内感染和严重需氧菌与厌氧菌混合感染的适用药物。

Study on the in vitro antibacterial activity of panipenem/betamipron

To evaluate the in vitro antimicrobial activity of panipenem/betamipron. The minimal inhibitory concentrations (MIC) of panipenem/betamipron against 247 clinical isolates was determined by agar dilution method.Compared with 5 other antimicrobial agents, the activity of panipenem against Haemophilus influenzae , Staphylococcus aureus containing methicillin resistant Staphylococcus aureus (MRSA) and Escherichia coli was slightly superior to that of imipenem; however, its antibacterial activity against Pseudomonas aeruginosia was about 1/4 that of imipenem. The antimicrobial activity of panipenem and imipenem against Gram negative bacteria such as Klebsiella pneumoniae and Enterobacter spp was slightly inferior to meropenem, superior to that of ceftazidime, cefoperazone/sulbactam and oxacillin. The activity of panipenem was affected by the inoculum size, pH of medium and adding of serum. Panipenem was the feasible antibiotics in treating hospital acquired infection caused by multi resistant bacteria, and the severe mix infections of aerobic and anaerobic bacteria.